Shilpa Medicare's Unit IV receives Eurasia GMP approval

Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia

Shilpa Medicare’s Unit VII, Nacharam, Hyderabad receives GMP certificate from EMA, Austria

The company has received the GMP Certification after successful closure of the inspection

India is the fourth largest medical devices market in Asia: Anupriya Patel

The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities

Pharmaceuticals & Medical Devices Bureau of India partnered with cooperative sector to open Jan Aushadhi Kendras through PACS

Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines

Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy

Amalgamation of Gujarat Themis Biosyn with Themis Medicare

The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL

Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu

This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing

Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate